• 1
    Stöckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148: 3027
  • 2
    Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000; 11: 8516
  • 3
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 6th edn. New York: Wiley & Sons, Inc., 2002
  • 4
    Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6: 15906
  • 5
    Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1: 1219
  • 6
    Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 4037
  • 7
    Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 106673
  • 8
    Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 10505
  • 9
    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495500
  • 10
    Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 45967
  • 11
    Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152: 814
  • 12
    Pianezza O, Meneguelo M, Merlo F et al. Adjuvant chemotherapy in locally advanced bladder cancer. Long-term follow-up of a multicenter study. J Urol 2003; 169 (Suppl.): 337
  • 13
    Otto T, Börgermann C, Krege S, Rübben H. Adjuvant chemotherapy in locally advanced bladder cancer [pT3/pT4a,pN1–2,M0]– a phase III study. Eur Urol 2001; 39 (Suppl. 2): 147
  • 14
    Advanced Bladder Cancer (ABC) Meta-analysis Trialists Group. Neoadjuvant chemotherapy in invasive bladder cancer. a systematic review and meta-analysis. Lancet 2003; 361: 192734
  • 15
    Advanced Bladder Cancer Meta-Analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005; 48: 189201
  • 16
    Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 244858
  • 17
    Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter phase III trial (AUO trial AB 5/95). J Clin Oncol 2005; 23: 496374
  • 18
    Leissner J, Hohenfellner R, Thüroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis. BJU Int 2000; 85: 81723
  • 19
    Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 2003; 170: 3541
  • 20
    Poulsen AL, Horn T, Steven K. Radical cystectomy. extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998; 160: 201520
  • 21
    Jin J, Lehmann J, Stöckle M, Steinberg G, Stadler W. Phase II trial of adjuvant gemcitabine plus cisplatin with amifostine cytoprotection in patients with locally advanced bladder cancer. J Clin Oncol 2005; 23: 16S, 426s, A4695